Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Oct 20, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.188, Linvoseltamab-gcpt (Lynozyfic)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Oct 20, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.188 has been established for Linvoseltamab-gcpt (Lynozyfic), a new medication. This creates new coverage and billing guidelines for this pharmaceutical product effective October 20, 2025.

Action Required

Action needed

Before October 20, 2025: Billing team must review the full policy MA08.188 for Linvoseltamab-gcpt (Lynozyfic) to understand coverage criteria, prior authorization requirements, and billing procedures for Medicare Advantage plans. Update billing system and staff training accordingly once complete policy details are available.

Related policy hubs

Independence Blue Cross policies Oncology Hematology